Clinical trials
Fallopian Tube Carcinoma clinical trials
Below are recruiting fallopian tube carcinoma clinical trials, each written for real people, not researchers. We’re tracking 81 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05092373RecruitingPhase 1
Tumor treating device plus targeted or immune drugs for advanced cancers
This Phase 1 study tests whether a tumor treating fields device works better when added to standard cancer drugs. It may help people with advanced solid tumors in the chest or belly, especially when standard treatment didn’t work or can’t be tolerated.
Houston, TexasAges 18 years+ - NCT05059444Recruiting
Blood test to catch cancer early after treatment
This study looks for signs of cancer left in the body after treatment using a simple blood test (called a liquid biopsy). It aims to see if the test can catch cancer that might come back earlier than regular scans.
Birmingham, AlabamaAges 18 years+ - NCT04919629RecruitingPhase 2
Tested treatments for recurrent ovarian cancer with fluid buildup
This Phase 2 study tests whether adding two medicines—APL-2 plus pembrolizumab or pembrolizumab plus bevacizumab—works better than bevacizumab alone for recurrent ovarian, fallopian tube, or primary peritoneal cancer. It also focuses on people who have symptoms from cancer-related fluid (ascites or pleural effusion).
Buffalo, New YorkAges 18 years+ - NCT04811703RecruitingPhase 1
Testing aerosol chemotherapy through the belly for advanced ovarian cancer
This Phase 1 study tests a new way to deliver chemotherapy inside the abdomen (belly) using a pressurized aerosol during a procedure, along with standard blood (IV) chemotherapy. It may help people with advanced ovarian cancer whose tumors have not progressed but are not removable with surgery yet.
LilleAges 18–75 - NCT04575935RecruitingPhase 3
Minimally invasive surgery after chemotherapy for advanced ovarian cancer
This trial studies whether doing surgery using smaller incisions after chemotherapy works as well as a more traditional approach for certain people with stage IIIC–IV ovarian, fallopian tube, or primary peritoneal cancer. It may help reduce surgical trauma while aiming for effective tumor removal.
Miami, FloridaAges 18 years+ - NCT04469764RecruitingPhase 2
Abemaciclib for certain recurrent ovarian or endometrial cancers
This Phase 2 study tests abemaciclib, a targeted pill treatment, for recurrent ovarian or endometrial cancer that shows specific tumor genetic patterns. It may help slow or control cancer growth in people whose tumor matches the required test results.
Los Angeles, CaliforniaAges Any age - NCT04055649RecruitingPhase 2
Test of ONC201 and weekly paclitaxel for platinum-resistant ovarian cancer
This Phase 2 study tests whether ONC201 given with weekly paclitaxel can control platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. It may help by shrinking tumors or slowing growth in people whose cancer has progressed after platinum chemotherapy.
Detroit, MichiganAges 18 years+ - NCT03968406RecruitingPhase 1
Talazoparib plus radiation for recurrent gynecologic cancers
This Phase 1 study tests whether the cancer drug talazoparib, combined with radiation, can better control recurrent gynecologic cancers in the pelvis/abdomen. It focuses on patients whose cancer has come back locally enough that radiation can be given, while other disease is not rapidly worsening.
Baltimore, MarylandAges 18 years+ - NCT03604315RecruitingPhase 1
PET/CT scan testing a new radioactive tracer for tumors
This early-phase study uses PET/CT scans to see how well a new radioactive tracer (a tiny dose of a special material) highlights solid tumors in the body. It may help researchers learn whether this tracer can better find and track tumor spots seen on standard scans.
Houston, TexasAges 18 years+ - NCT03296826Recruiting
Study for women with BRCA gene changes
This study follows women who carry BRCA1 or BRCA2 gene variants (or a gene variant of unclear meaning) to learn about their risks over time. It may help improve how genetic information is used to guide future care.
OkayamaAges 20 years+ - NCT06915025RecruitingPhase 3
Study of a new drug for advanced ovarian cancer
This trial tests a new drug called IMNN-001 combined with standard chemotherapy for women with advanced ovarian, fallopian tube, or peritoneal cancer. The goal is to see if adding this drug can improve safety and effectiveness.
Orlando, FloridaAges 18 years+ - NCT07772869Recruiting
Uterine washing test to detect ovarian cancer risk
This study is testing a new way to find ovarian cancer early. It uses a gentle washing of the uterus (like a Pap test) to collect cells and look for signs of cancer in women who are at high risk because of a BRCA gene mutation. The goal is to see if this method can detect cancer before it spreads, which might help save more lives.
Seattle, WashingtonAges 18 years+ - NCT06469281RecruitingPhase 1
A new immune cell therapy for recurring ovarian cancer
This early-phase trial tests a new immune cell therapy called 27T51, which targets a protein called MUC16 found on ovarian cancer cells. The study is for people with recurrent or treatment-resistant ovarian, primary peritoneal, or fallopian tube cancer to see if the therapy is safe and works when given alone or with other treatments.
Boston, MassachusettsAges 18 years+ - NCT04794322Recruiting
Testing uterine fluid to help detect ovarian cancer
This study checks whether a sample of fluid from the uterus (uterine lavage) can help detect ovarian or fallopian tube cancer. You may join if you are having certain gynecologic surgeries or, in a smaller group, you have a BRCA1/2 mutation.
Little Rock, ArkansasAges 30 years+ - NCT05579366RecruitingPhase 1/Phase 2
Study of rinatabart sesutecan for advanced solid tumors
This trial tests an investigational drug called rinatabart sesutecan (also known as Rina-S) for people with advanced solid tumors, including ovarian, endometrial, lung, breast, and other cancers. The drug is designed to target and kill cancer cells, and the study aims to see if it is safe and effective.
Phoenix, ArizonaAges 18 years+ - NCT05460000RecruitingPhase 2
Niraparib after early ovarian cancer chemo—short vs long
This trial tests whether taking niraparib (a maintenance anti-cancer pill) for a shorter time after 3 cycles of platinum chemotherapy works as well as taking it after 6 cycles. It is for people with advanced ovarian cancer that has been fully removed (no visible tumor) and is “HRD-positive,” meaning it has certain DNA repair weaknesses.
InnsbruckAges 18 years+ - NCT06792552RecruitingPhase 1
Study of SIM0505 for advanced solid tumors
This trial tests a new drug called SIM0505 for people with advanced solid tumors that have not responded to standard treatments. The study looks at different cancer types, including ovarian cancer, kidney cancer, uterine cancer, and lung cancer, to see if SIM0505 can help shrink tumors or slow their growth.
Orlando, FloridaAges 18 years+ - NCT05739981RecruitingPhase 1/Phase 2
Immunotherapy plus chemo for newly diagnosed advanced ovarian cancer
This trial tests an immune-based treatment (IMNN-001/GEN-1) combined with standard chemotherapy given before and during surgery. It’s for people with newly diagnosed advanced high-grade serous ovarian, fallopian tube, or primary peritoneal cancer to see if it can improve outcomes.
Baltimore, MarylandAges 18 years+ - NCT04606914RecruitingPhase 2
Carboplatin plus mirvetuximab for advanced ovarian cancer after chemo
This Phase 2 study tests adding mirvetuximab to carboplatin for people with advanced, high-grade serous ovarian cancer who will first receive “neoadjuvant” chemotherapy. It is designed for tumors that strongly show FRα, which mirvetuximab targets, to see if this improves outcomes.
Birmingham, AlabamaAges 18 years+ - NCT06638593Recruiting
Comparing open vs. robotic surgery for pelvic masses up to 8cm
This study compares two types of minimally invasive surgery—traditional laparoscopic (keyhole) versus robotic-assisted—for removing complex ovarian cysts or masses up to 8cm that haven't spread. The goal is to see which approach might offer better recovery and outcomes for women with these growths.
GuildfordAges 18–100 - NCT04196257RecruitingPhase 1
Early-dose trial of BP1001-A for advanced or recurrent solid tumors
This Phase 1 trial studies BP1001-A in people with advanced or recurring solid cancers to find a safe dose and learn how the treatment works. You may be asked for tumor biopsies before and possibly after treatment to see how the cancer responds.
Silver Spring, MarylandAges 18 years+ - NCT06466382Recruiting
Personalized therapy for advanced ovarian cancer
This study tests a personalized cancer therapy designed just for you and your tumor. It is for people with newly diagnosed advanced ovarian cancer who can wait a short time before starting treatment and plan to have surgery after 2 cycles of chemotherapy.
Baden, Canton of AargauAges 18 years+ - NCT06890338RecruitingPhase 2
Carboplatin and mirvetuximab for advanced ovarian cancer
This trial tests a combination of chemotherapy (carboplatin) and a targeted drug (mirvetuximab soravtansine) given through a vein. It is for people with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer that has a specific protein called folate receptor alpha (FRα) on at least 75% of tumor cells.
Birmingham, AlabamaAges 18 years+ - NCT05080556RecruitingPhase 2
Adaptive chemotherapy for ovarian cancer after platinum and PARP
This trial tests a personalized (adaptive) chemotherapy plan for people with certain types of ovarian/fallopian tube/peritoneal cancer who already had platinum chemotherapy and a PARP inhibitor. It’s for patients whose cancer came back after (or still responds to) prior platinum treatment and may help delay disease progression.
LondonAges 18 years+
Hear when a new Fallopian Tube Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for fallopian tube carcinoma?
- Yes. Clin2 currently lists 81 recruiting fallopian tube carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a fallopian tube carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a fallopian tube carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.